ArticleAmerican journal of physiology. Cell physiology2025
Hypothalamic gliosis as a potential mediator of improved glucose tolerance induced by time-restricted feeding in obese mice.
Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Time-restricted feeding (TRF) has been shown to improve glycemic control, reduce liver fat, and decrease cardiovascular risk in humans and diet-induced obese (DIO) mice. However, the mechanisms associated with this improvement are not completely understood. High-fat diet (HFD)-associated hypothalamic inflammation and glial activation promote obesity and metabolic dysfunction, raising the possibility that TRF mitigates these factors. Specifically, TRF increases circulating levels of β-hydroxybutyrate (BHB), a ketone body that crosses the blood-brain barrier and has anti-inflammatory properties. Here, we evaluated whether the beneficial effects of TRF are associated with changes in hypothalamic inflammation and gliosis. Furthermore, we assessed the ability of peripheral or central administration of BHB to mimic the metabolic phenotype of TRF. Consistent with prior studies in HFD-fed mice, weight loss induced by TRF was modest, due to a transient decrease in food intake offset by a persistent reduction in energy expenditure. Despite the limited effect on body weight and adiposity, TRF markedly improved glucose tolerance in DIO mice, restoring glucose homeostasis to the level of chow-fed controls. Unexpectedly, TRF increased hypothalamic markers of gliosis in DIO mice. Finally, although TRF induced the predicted rise in circulating BHB levels, chronic systemic or ICV administration of BHB had no effect on glucose tolerance and hypothalamic gliosis. Together, these data suggest that increased hypothalamic gliosis may contribute to the improvement of glucose tolerance induced by TRF in DIO mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.